0.3095  -0.023 (-6.81%)		04-24 11:34
Open: 0.3236 High: 0.3236 Volume: 1,026,113		Pre. Close: 0.3321 Low: 0.3085 Market Cap: 7(M)

Short term
Mid term
Targets	6-month :	0.5	1-year :	0.6
Resists	First :	0.43	Second :	0.51
Pivot price	0.37
Supports	First :	0.28	Second :	0.24
MAs	MA(5) :	0.33	MA(20) :	0.39
	MA(100) :	1.09	MA(250) :	2.19
MACD	MACD :	-0.1	Signal :	-0.2
%K %D	K(14,3) :	16.3	D(3) :	18.7
RSI	RSI(14): 32.4
52-week	High :	8.93	Low :	0.28

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ MDCX ] has closed above bottom band by 22.0%. Bollinger Bands are 54.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 21 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	0.34 - 0.34	0.34 - 0.34
Low:	0.32 - 0.32	0.32 - 0.32
Close:	0.33 - 0.33	0.33 - 0.33

Medicus Pharma Ltd. is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutic assets, with an emphasis on non-invasive treatments for skin cancer.

Thu, 23 Apr 2026
Medicus Pharma Ltd may offer and sell common shares up to $50 million aggregate through agents - marketscreener.com

Thu, 23 Apr 2026
MDCX (NASDAQ: MDCX) increases equity ATM to $50,000,000 with Maxim, Yorkville - Stock Titan

Thu, 23 Apr 2026
Medicus Pharma (MDCX) Stock: Important Info (Institutional Selling) 2026-04-22 - Popular Trader Picks - Cổng thông tin điện tử tỉnh Tây Ninh

Tue, 21 Apr 2026
Medicus Pharma (MDCX) asks shareholders to approve up to 50-for-1 reverse split - Stock Titan

Wed, 01 Apr 2026
Director Barry Fishman granted 25,000 Medicus Pharma (MDCX) stock options - Stock Titan

Wed, 01 Apr 2026
Director at Medicus Pharma (NASDAQ: MDCX) awarded 25,000 stock options at $0.50 - Stock Titan

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	0 (M)
Shares Float	39 (M)
Held by Insiders	3.282e+007 (%)
Held by Institutions	18.4 (%)
Shares Short	911 (K)
Shares Short P.Month	0 (K)

EPS	0
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-204.1 %
Return on Equity (ttm)	-2 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	-2.8 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	-23 (M)

PE Ratio	0
PEG Ratio	0
Price to Book value	0
Price to Sales	0
Price to Cash Flow	0

Dividend	0
Forward Dividend	1.99e+006
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.